StudiesStudies

Baseline Analysis of the Projected Impact of BRAC 2005 on Purchased Medical Care Costs

Objective: This study addresses two critical DoD leadership priorities: (1) ensuring the Affordability of the Enterprise, which, for the Unified Medical Program directly supports sustaining the medical benefit; and (2) Management of Human Capital in identifying factors affecting the peacetime health care benefit is available where the U.S.-based future forces, families and residual retiree beneficiaries are going to be, and not where they are today. The objective of this study is to estimate the residual population expected to remain in BRAC locations where direct medical care military treatment facility (MTF) capability will downsize or be eliminated and estimate the concomitant financial impact on purchased medical care costs associated with that residual population. This study will benefit TRICARE Operations managers responsible for managing the TRICARE benefit, TRICARE Resource managers responsible for allocating adequate financial resources between the direct and purchased care domains, and TRICARE Regional Offices responsible for managing the Health Care Support Contracts which establish sufficient civilian sources of care, pay claims for that care, and support MTF-based care to ensure adequate access to and satisfaction with the TRICARE benefit. The results are important in order to adequately plan and allocate sufficient resources to the purchased care domain, especially in light of efforts to sustain the benefit when demand, health care utilization, and associated costs for TRICARE are increasing, while individual cost-shares and premium payments have been level since the inception of the program in 1994.

Results:

Status: Active

> Return to complete list of studies

WARNING: This is a Department of Defense (DoD) interest computer system. The Military Health System Web Site is the Official Web Presence of the Office of the Assistant Secretary of Defense (Health Affairs) and the TRICARE Management Activity.